- Home
- SBFM vs HEPA Comparison
SBFM vs HEPA Comparison
Compare SBFM & HEPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBFM
- HEPA
- Stock Information
- Founded
- SBFM 2006
- HEPA 2013
- Country
- SBFM United States
- HEPA United States
- Employees
- SBFM N/A
- HEPA N/A
- Industry
- SBFM Biotechnology: Pharmaceutical Preparations
- HEPA Biotechnology: Pharmaceutical Preparations
- Sector
- SBFM Health Care
- HEPA Health Care
- Exchange
- SBFM Nasdaq
- HEPA Nasdaq
- Market Cap
- SBFM 3.7M
- HEPA 4.1M
- IPO Year
- SBFM N/A
- HEPA N/A
- Fundamental
- Price
- SBFM $2.90
- HEPA $0.47
- Analyst Decision
- SBFM Strong Buy
- HEPA
- Analyst Count
- SBFM 1
- HEPA 0
- Target Price
- SBFM $15.00
- HEPA N/A
- AVG Volume (30 Days)
- SBFM 151.9K
- HEPA 100.9K
- Earning Date
- SBFM 11-05-2024
- HEPA 11-14-2024
- Dividend Yield
- SBFM N/A
- HEPA N/A
- EPS Growth
- SBFM N/A
- HEPA N/A
- EPS
- SBFM N/A
- HEPA N/A
- Revenue
- SBFM $32,959,491.00
- HEPA N/A
- Revenue This Year
- SBFM $59.94
- HEPA N/A
- Revenue Next Year
- SBFM $164.69
- HEPA N/A
- P/E Ratio
- SBFM N/A
- HEPA N/A
- Revenue Growth
- SBFM 61.94
- HEPA N/A
- 52 Week Low
- SBFM $2.11
- HEPA $0.43
- 52 Week High
- SBFM $572.00
- HEPA $3.49
- Technical
- Relative Strength Index (RSI)
- SBFM 49.22
- HEPA 42.44
- Support Level
- SBFM $2.79
- HEPA $0.43
- Resistance Level
- SBFM $2.94
- HEPA $0.53
- Average True Range (ATR)
- SBFM 0.26
- HEPA 0.07
- MACD
- SBFM -0.03
- HEPA -0.01
- Stochastic Oscillator
- SBFM 16.70
- HEPA 13.36
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. The company is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA targeted for liver cancer, (ii) SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections, and (iii) Adva-27a for pancreatic cancer. The company has two reportable segments: Prescription Generic Pharmaceuticals ("Generic Pharmaceuticals") and Nonprescription Over-The-Counter Products ("OTC Products"). The company generates the majority of its revenue from the Generic Pharmaceuticals segment.
About HEPA Hepion Pharmaceuticals Inc.
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan-cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.